Sol-Gel Technologies (SLGL) Non Operating Income (2018 - 2026)
Sol-Gel Technologies (SLGL) reported Non Operating Income of -$128000.0 for Q1 2026, up 50.96% year-over-year from -$84791.9 in Q1 2025, and down 136.99% quarter-over-quarter from $346000.0 in Q3 2025.
Sol-Gel Technologies (SLGL) Non Operating Income (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 9 years of Non Operating Income data on file, last reported at -$128000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$128000.0, up 50.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $337000.0 (up 82.16% YoY), and the FY2023 annual result was $2.1 million, up 56.47% from the prior year.
- Non Operating Income eased to -$128000.0 in Q1 2026 per SLGL's latest filing, from $346000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $596000.0 in Q3 2023 and troughed at -$368000.0 in Q1 2024.
- A 5-year average of $141400.0 and a median of $346000.0 in 2025 frame the typical range for Non Operating Income.
- On a YoY basis, Non Operating Income climbed as much as 1457.14% in 2022 and fell as far as 3555.56% in 2022.
- A 5-year view of Non Operating Income shows it stood at $420000.0 in 2022, then surged by 35.95% to $571000.0 in 2023, then declined by 19.09% to $462000.0 in 2024, then dropped by 25.11% to $346000.0 in 2025, then sank by 136.99% to -$128000.0 in 2026.
- Business Quant data shows SLGL's Non Operating Income at -$128000.0 in Q1 2026, $346000.0 in Q3 2025, and $380000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | -128,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128,000.00 |
| Sep 30, 2025 | 346,000.00 |
| Jun 30, 2025 | 380,000.00 |
| Mar 31, 2025 | -261,000.00 |
| Sep 30, 2024 | 462,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Mar 31, 2024 | -368,000.00 |
| Dec 31, 2023 | 571,000.00 |
| Sep 30, 2023 | 596,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Mar 31, 2023 | -342,000.00 |
| Dec 31, 2022 | 420,000.00 |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | -329,000.00 |
| Mar 31, 2022 | -353,000.00 |
| Dec 31, 2021 | 73,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | -9,000.00 |
| Mar 31, 2021 | -161,000.00 |
| Dec 31, 2020 | 197,000.00 |